In the BioHarmony Drug Report Database
Naldemedine
Symproic, Rizmoic (naldemedine) is a small molecule pharmaceutical. Naldemedine was first approved as Symproic on 2017-03-23. It is used to treat constipation in the USA. It has been approved in Europe to treat constipation. The pharmaceutical is active against mu-type opioid receptor. In addition, it is known to target delta-type opioid receptor. Symproic’s patents are valid until 2033-05-13 (FDA).
Trade Name
|
Rizmoic |
|---|---|
Common Name
|
naldemedine |
ChEMBL ID
|
CHEMBL2105755 |
Indication
|
constipation |
Drug Class
|
Narcotic agonists/antagonists (normorphine type) |
Image (chem structure or protein)